Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Celularity stock

Learn how to easily invest in Celularity stock.

Celularity Inc is a shell companies business based in the US. Celularity shares (GXGX) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Celularity

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GXGX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Celularity stock price (NASDAQ: GXGX)

Use our graph to track the performance of GXGX stocks over time.

Celularity shares at a glance

Information last updated 2021-09-12.
Latest market close$10.13
52-week range$7.73 - $12.58
50-day moving average $10.06
200-day moving average $10.14
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.49

Buy Celularity shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
Stocks, ETFs, Cryptocurrency
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Axos Bank Self Directed Investing
when you open an account and deposit at least $1500.
Vanguard Personal Advisor
Stocks, Mutual funds, ETFs
Financial advice powered by relationships, not commissions.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Celularity stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Celularity price performance over time

Historical closes compared with the close of $10.13 from 2021-05-28

1 week (2022-06-19) N/A
1 month (2022-05-26) N/A
3 months (2022-03-26) N/A
6 months (2021-12-26) N/A
1 year (2021-06-30) -0.49%
2 years (2020-06-30) -0.69%
3 years (2019-06-26) N/A
5 years (2017-06-26) N/A

Celularity financials

Gross profit TTM $0
Return on assets TTM -1.29%
Return on equity TTM -52.61%
Profit margin 0%
Book value $0.67
Market capitalisation $201.6 million

TTM: trailing 12 months

Celularity share dividends

We're not expecting Celularity to pay a dividend over the next 12 months.

Celularity overview

Celularity Inc. , a biopharmaceutical company, develops placental-derived off-the-shelf therapeutic and cellular medicines for cancer, infectious diseases, and degenerative diseases. The company offers Biovance, a human amniotic membrane allograft that provides a protective cover and supports the body's wound healing processes; and Interfyl, a connective tissue matrix for various surgical applications when there is a need to replace and supplement damaged or inadequate integumental tissue. It also offers allogeneic placenta-derived cell therapy product candidates. The company was incorporated in 2016 and is based in Florham Park, New Jersey. .

Frequently asked questions

What percentage of Celularity is owned by institutions?
Currently 83.535% of Celularity shares are held by institutions.
When does the fiscal year end for Celularity?
Celularity's fiscal year ends in December.
Where is Celularity based?
Celularity's address is: 170 Park Ave, Florham Park, NJ, United States, 07932
What is Celularity's ISIN number?
Celularity's international securities identification number is: US1511901050

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site